|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||125.00 / 234.93|
These two firms have successful drugs and could make nice additions for larger companies.
Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
I still believe it will be a big year for buyouts across the biotech industry.
Stocks ended lower Wednesday as investors found little in Donald Trump's State of the Union address to warrant extending recent market gains.
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
U.S. stock futures mixed as investors remain worried the U.S. and China could fail to reach a trade agreement following Donald Trump's State of the Union address; Walt Disney rises as earnings beat estimates but expenses could rise from the company's new digital offerings; Snap soars as losses narrow and its user growth stabilizes.
These high risk/high reward oncology names look significantly undervalued, right now.
These themes are working despite the turmoil in Washington and slowing global growth.
I would add to them on any significant dips in the market.
Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.
My stated reason for being in Pfizer all along has been price stability and income.
I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.
This is the kind of reversal that happens in a bull market.
Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.
Could there be more M&A this year than Wall Street had thought? Also, GE's quest for more liquidity took another baby step Monday.
Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.
Tesla, the big pharma mergers and General Electric are some of the top stories on TheStreet.
Luxoft is to be bought for about $2 billion by DXC Technology.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.
The company expects revenue to jump 12% year over year.
Eli Lilly & Co. says Monday it will pay $8 billion in cash for cancer drug specialists Loxo Oncology in the second major pharmaceutical sector deal of the year.
Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.